RANI (Rani Therapeutics Holdings) Research & Development: $18.80 Mil (TTM As of Mar. 2026)


RANI Rani Therapeutics Holdings Inc RANI
32 GF Score
Price $0.74
! 3 Warning Signs
View Full Analysis

What is Rani Therapeutics Holdings Research & Development?

Rani Therapeutics Holdings RANI -3.22% 32 Research & Development is $18.80 Mil as of Mar. 2026. GuruFocus rates RANI with a GF Score™ of 32/100. The stock has 3 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Rani Therapeutics Holdings's Research & Development for the three months ended in Mar. 2026 was $5.16 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was $18.80 Mil.

Rani Therapeutics Holdings  (NAS:RANI) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Rani Therapeutics Holdings Research & Development Related Terms

Rani Therapeutics Holdings Research & Development Historical Data

* Premium members only.

The historical data trend for Rani Therapeutics Holdings's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Rani Therapeutics Holdings Research & Development Chart

Rani Therapeutics Holdings Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial 26.48 36.61 39.62 26.68 20.21

Rani Therapeutics Holdings Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.57 5.51 3.22 4.91 5.16
RANI
32GF Score
Rani Therapeutics Holdings Inc RANI
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Rani Therapeutics Holdings Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $18.80 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of $18.80 Mil mean?
Rani Therapeutics Holdings (RANI) has a Research & Development of $18.80 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Rani Therapeutics Holdings and its competitors.
Is Rani Therapeutics Holdings' Research & Development too high?
Rani Therapeutics Holdings' current Research & Development is $18.80 Mil. Overall, Rani Therapeutics Holdings has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Rani Therapeutics Holdings' Research & Development compare to CGTX and INO?
Rani Therapeutics Holdings' Research & Development of $18.80 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Rani Therapeutics Holdings and its competitors. Rani Therapeutics Holdings's current Research & Development is $18.80 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rani Therapeutics Holdings stock overvalued right now?
Rani Therapeutics Holdings (RANI) has a current Research & Development of $18.80 Mil. The current Research & Development is $18.80 Mil. Rani Therapeutics Holdings' overall GF Score™ is 32/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Rani Therapeutics Holdings (RANI), the current Research & Development is $18.80 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Rani Therapeutics Holdings Business Description

Address 2051 Ringwood Avenue, San Jose, CA, USA, 95131
Rani Therapeutics Holdings Inc is a clinical-stage biotherapeutics company advancing technologies to enable the development of orally administered biologics to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. The company has developed the RaniPill capsule, which is designed to deliver a wide variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. RaniPill is a proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing. The company is also engaged in developing RaniPill HC, which is intended to enable the delivery of drug payloads in liquid form with high bioavailability.
32GF Score

Get the complete analysis for RANI

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.74
Price